Search

Displaying results 4321 - 4330 of 4822 in total
  1. Drug

    Ramosetron

    go.drugbank.com/drugs/DB09290
    Investigational

    It is believed to have higher potency and longer antiemetic action than other 1st generation 5-HT3 antagonists such as ondansetron.

  2. Drug

    J147

    go.drugbank.com/drugs/DB13957
    Experimental

    [A31606,A31607,A31608] It is a curcumin derivative and a potent neurogenic and neuroprotective drug candidate initially developed for the treatment of neurodegenerative conditions associated with aging

  3. Drug

    AZD7442

    go.drugbank.com/drugs/DB15787
    Investigational

    [L15596] It was developed by AstraZeneca with the goal of conferring at least 6 months of protection against COVID-19 - a significantly longer window of efficacy than that of other vaccines.[L15591]

  4. Drug

    OAV201

    go.drugbank.com/drugs/DB17842
    Experimental

    It was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661]

  5. Drug

    Etryptamine

    go.drugbank.com/drugs/DB01546
    ApprovedIllicitWithdrawn

    αET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound.

  6. Drug

    Elagolix

    go.drugbank.com/drugs/DB11979
    ApprovedInvestigational

    It has been determined that endometriosis is one of the most common gynecologic disorders in the United States [A35868, A35869, F801].

  7. Drug

    Pagoclone

    go.drugbank.com/drugs/DB04903
    Investigational

    It is one of a relatively recently developed class of medicines known as the nonbenzodiazepines, which have similar effects to the older benzodiazepine group, but with quite different chemical structures

  8. Drug

    PSN9301

    go.drugbank.com/drugs/DB05001
    Experimental

    PSN9301 has a very rapid onset and a relatively short duration of action, and available pre-clinical and clinical data indicate that it may be an ideal product candidate for meal-related dosing.

  9. Drug

    SC12267

    go.drugbank.com/drugs/DB05125
    Investigational

    Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important for the immune response.

  10. Drug

    Gevokizumab

    go.drugbank.com/drugs/DB12119
    Investigational

    It has a very high binding affinity of 300fM and blocks the activation of IL-1 receptors.